SCHEMBL30683070

SCHEMBL30683070

CN1C(=O)Cc2ccc(Br)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.47
CASP2 P42575 1/20 0.46
CCNB2 O95067 1/20 0.44
CDK1 P06493 1/20 0.44
CCNB1 P14635 1/20 0.44
GSK3B P49841 1/20 0.44
CCNB3 Q8WWL7 1/20 0.44
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
ALOX15 P16050 1/20 0.43
ALOX12 P18054 1/20 0.43
HBB P68871 1/20 0.43
KMT2A Q03164 1/20 0.43
HSD17B10 Q99714 1/20 0.43
SRD5A1 P18405 2/20 0.42
GABRA1 P14867 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL290257 1.00 IDO1 (0.47) IDO1CASP2CCNB2CDK1CCNB1
SCHEMBL746154 0.85 IDO1 (0.57) IDO1CASP2CCNB2CDK1CCNB1
SCHEMBL31711769 0.84 BRD4 (0.41) CASP2MEN1MAPTALOX15ALOX12
SCHEMBL17419131 0.84 SRD5A1 (0.55) CASP2SRD5A1GABRA1GABRG2GABRB3
SCHEMBL31597788 0.84 SRD5A1 (0.55) CASP2SRD5A1GABRA1GABRG2GABRB3
SCHEMBL29134370 0.83 CASP2 (0.42) IDO1CASP2CCNB2CDK1CCNB1
SCHEMBL30015775 0.83 CASP2 (0.42) IDO1CASP2CCNB2CDK1CCNB1
SCHEMBL22290609 0.81 SRD5A1 (0.46) CASP2SRD5A1GABRA1GABRG2GABRB3
SCHEMBL30832142 0.81 SRD5A1 (0.46) CASP2SRD5A1GABRA1GABRG2GABRB3
SCHEMBL5986263 0.79 HSD17B10 (0.47) MEN1KMT2AHSD17B10SRD5A1METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747242-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE Horizon Therapeutics Ireland Dac (IE) 2026-05-27 EP disclosed
US-20250250232-A1 AZETIDINE DERIVATIVES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2025-08-07 US disclosed
WO-2025019715-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-01-23 WO disclosed
WO-2023239645-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250250232-A1 AZETIDINE DERIVATIVES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS DPP9, DPP4, DPP3 IDO1 270/4885CASP2 2404/4885CCNB2 4859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.